Download NEWS YOU CAN USE 2015 03 UPD

News You Can Use…
Pete Koval, PharmD
Alvin Oung, PharmD
Cone Health Family Medicine
March 2015
News You Can Use…
This news cycles automatically
& IS INTENDED to provide
incentive to arriving early!
Thanks for coming early!
New Drug Approval
• Avycaz (ceftazidime + avibactam) received
FDA approval for the treatment of
complicated intra-abdominal infections, in
combination with metronidazole, and
complicated urinary tract infections,
including pyelonephritis
• This is the 2nd cephalosporin/β-lactamase inhibitor
combination approved for use in patients who have
limited or no alternative treatments in cIAIs and/or
cUTIs
• Zerbaxa (ceftolazane + tazobactam) was approved in
December 2014
02/25/2015 FDA News and Events
New Drug Approval
• Savaysa (edoxaban) received FDA approval
for the treatment of DVT/PE and prevention of
stroke and systemic embolism in patients
with nonvalvular atrial fibrillation
• Similar MOA to rivaroxaban and apixaban
• Shown to have similar efficacy and reduced
bleeding risk compared to warfarin but with
various restrictions, ex: contraindicated in CrCl >
95 ml/min
01/08/2015 CenterWatch
New Drug Approval
• Toujeo (insulin glargine [rDNA origin]
injection, 300 U/ml]), a once-daily long-acting
basal insulin, received FDA approval to treat
Type 1 and Type 2 diabetes
• Same active ingredient as Lantus, but at three
times the concentration and suggested to have a
design to release insulin more gradually
• Lower rates of hypoglycemia were seen in
clinical trials by not mentioned in the FDAapproved label
02/25/2015 FDA News and Events
In the pipeline
• Novo Nordisk announced that it has
successfully completed its Phase 2 trial
for once-daily oral semaglutide vs onceweekly subcutaneously administered
semaglutide (in Phase 3)
• This would be the first oral GLP-1 receptor
agonist for the treatment of Type 2
diabetes
02/20/2015 ClinicalTrials.gov
New Drug Approval
• Farydak (panobinostat) received FDA
approval for the treatment of patients
with multiple myeloma
• This is the first HDAC (histone
deacetylase) inhibitor approved to treat
multiple myeloma
• Intended to be used in combination with
bortezomib and dexamethasone
02/23/2015 FDA News and Events
New Drug Approval
• Lucentis (ranbizumab) 0.3 mg injection
received expanded approval from the FDA to
treat diabetic retinopathy in patients with
diabetic macular edema
• The FDA previously had approved Lucentis to
treat DME and macular edema secondary to
retinal vein occlusions
• Lucentis is also approved to treat wet age-
related macular degeneration
02/06/2015 FDA News and Events
Hepatitis C Medication Updates
• Daclatasvir, with sofosbuvir, shows 97% SVR12
rates in genotypes 1-4 with co-infected HIV
patients in Phase 2 Trials
• Gilead announces 96% SVR12 Rates from Phase 3
Study evaluating Harvoni (ledipasvir
90mg/sofosbuvir 400mg) for Hepatitis C
genotypes 1 or 4 among patients co-infected with
HIV on ART
• Plans to file supplemental New Drug
Application
02/26/2015 Hepatitis C New Drug Research
New Drug Approval
• Cosentyx (secukinumab) received
approval from the FDA for the treatment
of moderate to severe plaque psoriasis
• This is the first approved human
monoclonal antibody that selectively
inhibits IL-17A
01/21/2015 FDA News and Events